Q-omics provides the consensus-scored LILRA1 profile across patient tissues and cancer cell-line models. LILRA1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LILRA1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, LILRA1 RNA expression shows 17,757 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where LILRA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LILRA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LILRA1 survival associations across molecular data types. LILRA1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LILRA1 RNA expression–survival associations across cancer types. High LILRA1 expression shows unfavorable associations in LGG and LAML, but favorable associations in HNSC, SKCM, KIRC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LILRA1 RNA expression.
This table summarizes LILRA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LILRA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LILRA1 shows lower tumor expression in LUAD, LUSC, LIHC and KICH and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher LILRA1 RNA expression in tumor versus normal tissue (log2 FC = +1.256, t-test p < 0.001).
This table shows molecular features associated with LILRA1 in patient tissues and cancer cell lines. In patient samples, LILRA1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LILRA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
